Eli Lilly 2006 Annual Report Download - page 8

Download and view the complete annual report

Please find page 8 of the 2006 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 116

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116

PORTFOLIO AND PIPELINE
6
Innovation at Lilly: The Portfolio and the Pipeline
Major Marketed Products (Dates indicate the year of fi rst global launch)
2005 Byetta® for type 2 diabetes
(codeveloped with Amylin Pharmaceuticals, Inc., and copromoted with Amylin
in the U.S.)
2004 Cymbalta® for major depressive disorder
for diabetic peripheral neuropathic pain (2004)
(copromoted with Quintiles Transnational Corp. in the U.S., and with Boehringer
Ingelheim elsewhere in the world, except Japan)
Alimta® for malignant pleural mesothelioma
for second-line treatment of non-small-cell lung cancer (2004)
Symbyax® for bipolar depression
Yentreve® for stress urinary incontinence (approved and launched outside the U.S.)
2003 Cialis® for erectile dysfunction
(developed by Lilly ICOS in a joint venture with ICOS Corp.; copromoted by
Lilly ICOS in North America and Europe and by Lilly elsewhere)
Strattera® for attention-defi cit hyperactivity disorder in children, adolescents, and adults
2002 Forteo® for treatment of men and postmenopausal women with osteoporosis who are at
high risk for a fracture
2001 Xigris® for adult severe sepsis patients at high risk of death
1999 Actos® for type 2 diabetes
(developed by Takeda Chemical Industries, Ltd., and copromoted with Takeda)
1998 Evista® for prevention of osteoporosis in postmenopausal women
for treatment of osteoporosis in postmenopausal women (1999)
1996 Zyprexa® for schizophrenia
for acute bipolar mania (2000)
Zyprexa® Zydis® tablet (2000)
for schizophrenia maintenance (2001)
as combination therapy with lithium or valproate for acute bipolar mania (2002)
for bipolar maintenance (2003)
Rapid-acting IntraMuscular formulation (2004)
Zyprexa® granules (2004; launched in Japan only)
Humalog® for treatment of type 1 and type 2 diabetes
Humalog® mixtures (1999)
Humalog® Mix 50/50 (1999)
1995 Gemzar® for non-small-cell lung cancer
for pancreatic cancer (1996)
for bladder cancer (1999; approved and launched outside the U.S.)
for metastatic breast cancer (2003)
for recurrent ovarian cancer (2004)
ReoPro® for prevention of cardiac ischemic complications in patients undergoing
coronary intervention, such as angioplasty
for unstable angina associated with stent procedure (1997)
(developed by Centocor and promoted by Lilly, except in Japan)